Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

被引：0
|
作者：
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构：
[1] 900 Walnut Street,Jefferson Hospital for Neuroscience
[2] Second Floor,Montefiore Headache Center, Department of Neurology, Department of Epidemiology and Population Health
[3] Suite #200,Headache Center of Southern California
[4] University of South Alabama College of Medicine,undefined
[5] George Washington School of Medicine,undefined
[6] Allergan plc,undefined
[7] Albert Einstein College of Medicine,undefined
[8] The Neurology Center,undefined
来源：
The Journal of Headache and Pain | 2019年 / 20卷
关键词：
COMPEL; onabotulinumtoxinA; Migraine; Allodynia; Disability; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Effects of OnabotulinumtoxinATreatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis
    Young, W. B.
    Lopez, J.
    Rothrock, J. F.
    Manack, Adams A.
    Blumenfeld, A. M.
    HEADACHE, 2017, 57 : 170 - 171
  • [32] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Blumenfeld, Andrew M.
    Stark, Richard J.
    Freeman, Marshall C.
    Orejudos, Amelia
    Adams, Aubrey Manack
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [33] Efficacy, tolerability, and safety of onabotulinumtoxinA treatment for chronic migraine in patients with acute medication overuse: analysis of the PREEMPT and COMPEL trials
    Agosti, R.
    Straube, A.
    Diener, H. C.
    Freeman, M.
    Pascual Gomez, J.
    Seminerio, M.
    Delahaye, L.
    Stark, R. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [34] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Andrew M. Blumenfeld
    Richard J. Stark
    Marshall C. Freeman
    Amelia Orejudos
    Aubrey Manack Adams
    The Journal of Headache and Pain, 2018, 19
  • [35] Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study
    Mari, Zoltan
    Dashtipour, Khashayar
    Jankovic, Joseph
    Adler, Charles H.
    Schwartz, Marc
    Brin, Mitchell F.
    NEUROLOGY, 2017, 88
  • [36] LONG-TERM SAFETY AND TOLERABILITY OF ONABOTULINUMTOXINA TREATMENT IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: COMPEL ANALYSIS BY TREATMENT CYCLE
    Winner, P. K.
    Blumenfeld, A. M.
    Eross, E. J.
    Orejudos, A.
    Adams, A. Manack
    Brin, M. F.
    CEPHALALGIA, 2018, 38 : 75 - 76
  • [37] Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD probe study
    Dashtipour, K.
    Mari, Z.
    Jankovic, J.
    Adler, C.
    Schwartz, M.
    Brin, M.
    MOVEMENT DISORDERS, 2017, 32
  • [38] OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study
    Jost, W.
    Ellenbogen, A.
    Wittenberg, G.
    Ngo, K.
    Largent, J.
    Zuzek, A.
    Francisco, G.
    Esquenazi, A.
    MOVEMENT DISORDERS, 2019, 34 : S561 - S561
  • [39] ONABOTULINUMTOXINA IS WELL TOLERATED IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: LONG-TERM COMPEL ANALYSIS BY TREATMENT CYCLE
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Brin, Mitchell F.
    TOXICON, 2018, 156 : S114 - S114
  • [40] Comparative Insights into Physiotherapy Expectations Among Chronic Migraine Patients with and without OnabotulinumtoxinA Treatment: A Case–Control Study
    Dilara Onan
    Halime Arıkan
    İrem Can
    Aynur Özge
    Paolo Martelletti
    SN Comprehensive Clinical Medicine, 6 (1)
12345